News from Futu Information on March 30, this Wednesday $RECBIO-B (02179.HK)$ An announcement was issued. The company issued 30854,500 shares, priced at HK$24.8 per share, and 500 shares per lot. It is expected to go public on March 31.
During the public offering phase, Ricoh Biotech received about 10.65 times more subscriptions, and the final number of offered shares distributed to the public sale was 3,085,500 shares, accounting for about 10% of the total number of shares offered (before any over-allotment rights were exercised). A total of 7853 valid applications were received, with a first-hand winning rate of 9.28%, and a stable first-hand purchase of 12 lots.
Furthermore, the international offering has been slightly oversubscribed (about 1.39 times), and the final number of shares offered was 277.69 million shares, which is equivalent to about 90% of the total number of shares offered (before any over-allotment rights are exercised). Futu News has compiled relevant data in the following table:
The net proceeds of about HK$672 million will be used for the following purposes: about 47.3% will be distributed to the HPV vaccine pipeline of companies that continue to optimize, develop and commercialize, including core products (recombinant HPV nine-valent vaccine REC603); about 17.7% will be used for pre-clinical and clinical research and registration of the COVID-19 vaccine (i.e. reCoV); about 21.1% will be used for pre-clinical and clinical research and registration of other vaccine candidates; about 6.7% will be used to further strengthen R&D capabilities and improve operational efficiency; about 7.2% will be used for the company's operations...